Cadrenal Therapeutics, Inc. Common Stock
CVKD
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.5M
$0.97
▼ -2.02%
P/E
—
Mkt Cap
$3.5M
52-Wk Range
$0.85–$14.50
52-Week Range
$0.85 - $14.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 92.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Orphan Drug Designation for Tecarfarin providing market exclusivity
- Novel mechanism of action addressing underserved patient population
- Clinical development stage with potential for accelerated FDA pathways
- Specialized focus on ESRD and atrial fibrillation comorbidity
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Stable outlook
Phase 2 clinical trial progression and positive efficacy data
Value
Valuation data unavailable
Momentum
Falling
-68.7% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying CVKD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$1.14 vs -$1.42 consensus (+19.7% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+19.7%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CVKD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related